<?xml version='1.0' encoding='utf-8'?>
<document id="30348903"><sentence text="Mechanistic In Vitro Studies Indicate that the Clinical Drug-Drug Interaction between Telithromycin and Simvastatin Acid Is Driven by Time-Dependent Inhibition of CYP3A4 with Minimal Effect on OATP1B1."><entity charOffset="86-99" id="DDI-PubMed.30348903.s1.e0" text="Telithromycin" /><entity charOffset="104-120" id="DDI-PubMed.30348903.s1.e1" text="Simvastatin Acid" /><pair ddi="false" e1="DDI-PubMed.30348903.s1.e0" e2="DDI-PubMed.30348903.s1.e0" /><pair ddi="false" e1="DDI-PubMed.30348903.s1.e0" e2="DDI-PubMed.30348903.s1.e1" /></sentence><sentence text="A previous attempt to accurately quantify the increased simvastatin acid exposure due to drug-drug interaction (DDI) with coadministered telithromycin, using a mechanistic static model, substantially underpredicted the magnitude of the area under the plasma concentration-time curve ratio (AUCR) based on reversible inhibition of CYP3A4 and organic anion transporting polypeptide 1B1 (OATP1B1)"><entity charOffset="56-72" id="DDI-PubMed.30348903.s2.e0" text="simvastatin acid" /><entity charOffset="137-150" id="DDI-PubMed.30348903.s2.e1" text="telithromycin" /><pair ddi="false" e1="DDI-PubMed.30348903.s2.e0" e2="DDI-PubMed.30348903.s2.e0" /><pair ddi="false" e1="DDI-PubMed.30348903.s2.e0" e2="DDI-PubMed.30348903.s2.e1" /></sentence><sentence text=" To reconcile this disconnect between predicted and clinically observed AUCR, telithromycin was evaluated as a time-dependent inhibitor of CYP3A4 in vitro, as well as an inhibitor of OATP1B1"><entity charOffset="72-76" id="DDI-PubMed.30348903.s3.e0" text="AUCR" /><entity charOffset="78-91" id="DDI-PubMed.30348903.s3.e1" text="telithromycin" /><pair ddi="false" e1="DDI-PubMed.30348903.s3.e0" e2="DDI-PubMed.30348903.s3.e0" /><pair ddi="false" e1="DDI-PubMed.30348903.s3.e0" e2="DDI-PubMed.30348903.s3.e1" /></sentence><sentence text=" Telithromycin inhibited OATP1B1-mediated [3H]-estradiol 17β-d-glucuronide (0"><entity charOffset="1-14" id="DDI-PubMed.30348903.s4.e0" text="Telithromycin" /><entity charOffset="42-74" id="DDI-PubMed.30348903.s4.e1" text="[3H]-estradiol 17β-d-glucuronide" /><pair ddi="false" e1="DDI-PubMed.30348903.s4.e0" e2="DDI-PubMed.30348903.s4.e0" /><pair ddi="false" e1="DDI-PubMed.30348903.s4.e0" e2="DDI-PubMed.30348903.s4.e1" /></sentence><sentence text="02 µM) transport with a mean IC50 of 12" /><sentence text="0 ± 1" /><sentence text="45 µM and was determined by IC50 shift and kinetic analyses to be a competitive reversible inhibitor of CYP3A4-mediated midazolam1- hydroxylation with a mean absolute inhibition constant (Ki) value of 3" /><sentence text="65 ± 0" /><sentence text="531 µM" /><sentence text=" The 2" /><sentence text="83-fold shift in IC50 (10" /><sentence text="4-3" /><sentence text="68 µM) after a 30-minute metabolic preincubation confirmed telithromycin as a time-dependent inhibitor of CYP3A4; the mean inhibitor concentration that causes half-maximal inactivation of enzyme (KI) and maximal rate of inactivation of enzyme (kinact) values determined for inactivation were 1"><entity charOffset="59-72" id="DDI-PubMed.30348903.s13.e0" text="telithromycin" /></sentence><sentence text="05 ± 0" /><sentence text="226 µM and 0" /><sentence text="02772 ± 0" /><sentence text="00272 min-1, respectively" /><sentence text=" After the integration of an enzyme time-dependent inhibition component into the previous mechanistic static model using the in vitro inhibitory kinetic parameters determined above, the newly predicted simvastatin acid AUCR (10"><entity charOffset="202-218" id="DDI-PubMed.30348903.s18.e0" text="simvastatin acid" /><entity charOffset="219-234" id="DDI-PubMed.30348903.s18.e1" text="AUCR" /><pair ddi="false" e1="DDI-PubMed.30348903.s18.e0" e2="DDI-PubMed.30348903.s18.e0" /><pair ddi="false" e1="DDI-PubMed.30348903.s18.e0" e2="DDI-PubMed.30348903.s18.e1" /></sentence><sentence text="8 or 5" /><sentence text="4) resulting from perturbation of its critical disposition pathways matched the clinically observed AUCR (10"><entity charOffset="100-103" id="DDI-PubMed.30348903.s20.e0" text="AUCR" /></sentence><sentence text="8 or 4" /><sentence text="3) after coadministration, or staggered administration, with telithromycin, respectively"><entity charOffset="61-74" id="DDI-PubMed.30348903.s22.e0" text="telithromycin" /></sentence><sentence text=" These results indicate the time-dependent inhibition of CYP3A4 by telithromycin as the primary driver underlying its clinical DDI with simvastatin acid"><entity charOffset="67-80" id="DDI-PubMed.30348903.s23.e0" text="telithromycin" /><entity charOffset="136-152" id="DDI-PubMed.30348903.s23.e1" text="simvastatin acid" /><pair ddi="false" e1="DDI-PubMed.30348903.s23.e0" e2="DDI-PubMed.30348903.s23.e0" /><pair ddi="false" e1="DDI-PubMed.30348903.s23.e0" e2="DDI-PubMed.30348903.s23.e1" /></sentence><sentence text="" /></document>